BTCC
/
BTCC Square
/
Global Cryptocurrency
/
BioNTech Stock Surges on Promising Cancer Drug Trial Results
BioNTech Stock Surges on Promising Cancer Drug Trial Results
8
3
BTCCSquare news:
BioNTech's American depositary receipts (ADRs) jumped 10% following positive phase 3 clinical trial results for its cancer drug trastuzumab pamirtecan. The antibody-drug conjugate, developed with China's Duality Biologics, met its primary endpoint in treating metastatic breast cancer patients.
The partners aim to submit biologics license applications in China, the EU, and the US. This marks BioNTech's first late-stage oncology drug to achieve this milestone, reigniting investor enthusiasm for the biotech firm beyond its pandemic-era vaccine success.
By:
